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1  | INTRODUCTION
In February 2015, WHO recommended that the 2015/16 Northern 
Hemisphere trivalent influenza vaccine should include the same influ-
enza A(H1N1)pdm09 strain as the 2014/15 season vaccine (the same 
component for the trivalent vaccine since the 2010/11 season), but 
different influenza A(H3N2) and B components, namely a virus from 
the 3C.3a A(H3N2) genetic group and the genetic group 3 of the B/
Yamagata lineage. The recommended strains were as follows: an in-
fluenza A/California/7/2009 (H1N1)pdm09- like virus, an influenza 
A/Switzerland/9715293/2013 (H3N2)- like virus and an influenza B/
Phuket/3073/2013- like Yamagata lineage virus.
An interim analysis for the 2015/16 season published in early February 
2016 from the European I- MOVE/I- MOVE+ multicentre case- control 
study showed a predominance of A(H1N1)pdm09 (71%, 246/348), with 
influenza B cocirculating (22%; 77/348) among participating study sites.1 
Among the B specimens where lineage information was available, 97.3% 
(36/37) were of the B/Victoria lineage, indicating a mismatch with the 
influenza B/Yamagata virus included in the trivalent vaccine.
In this eighth season of the I- MOVE/I- MOVE+ multicentre case- 
control study, we aimed to measure end- of- season 2015/16 vaccine 
effectiveness against influenza A(H1N1)pdm09 and influenza B, by 
age group, vaccine type, by prior (2014/15) vaccination status and 
by time since vaccination and for the total population and the target 
group for vaccination.
Nine of twelve study sites also participated in a pilot laboratory 
project where they randomly selected specimens for sequencing of 
at least the gene segment coding for the haemagglutinin, in order to 
compute a representative VE estimate against the influenza A(H1N1)
pdm09 6B.1 genetic group.
2  | METHODS
Twelve European study sites located in Croatia, France, Germany, 
Hungary, Ireland, Italy, Poland, Portugal, Romania, Spain, Sweden and 
the Netherlands participated in the test- negative 2015/16 multicentre 
case- control study. The methods have been described previously2-4 
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and are based on the ECDC generic case- control study protocol and 
the I- MOVE+ protocol.5,6
Participating practitioners interviewed and collected nasopha-
ryngeal or combined naso- and oropharyngeal specimens from a sys-
tematic sample of consenting patients seeking medical attention for 
influenza- like illness (ILI). In Hungary, only patients aged 18 years and 
older and in Croatia only patients aged 65 years and older were eligi-
ble. Practitioners collected in a standardised report form information 
including symptoms, date of onset and swabbing, 2015/16 seasonal 
vaccination status, date of influenza vaccination and vaccine product, 
prior (2014/15) seasonal vaccination status, sex, age and presence of 
chronic medical conditions in the past 12 months.
Seven study sites included a question on belonging to the tar-
get group for vaccination. In France, Germany, Poland, Portugal and 
Sweden, the target group was defined from patients’ information on 
age, chronic conditions and pregnancy. Additionally, in Portugal, being 
a health professional or carer and a cohabitant or carer of a patient 
at risk aged less than 6 months and in Poland, belonging to an occu-
pational risk group (eg, healthcare worker), defined the target group.
In the pooled analysis, we included patients meeting the European 
Union ILI case definition,7 swabbed within 7 days of symptom onset, 
and who had not received antivirals in the 14 days prior to swabbing.
A case of confirmed influenza was an ILI patient who was 
swabbed and tested positive for influenza virus using real- time 
reverse- transcription polymerase chain reaction (RT- PCR). Controls 
were ILI patients who tested negative for any influenza virus using 
RT- PCR.
We defined a person as vaccinated if he or she had received at 
least one dose of a 2015/16 seasonal influenza vaccine more than 14 
days before ILI symptom onset. Those vaccinated less than 15 days 
before ILI onset were excluded. All other patients were classified as 
unvaccinated.
For each study site, we included ILI patients presenting more than 
14 days after the start of national or regional influenza vaccination 
campaigns and we excluded controls presenting before the onset 
week of the first influenza type/subtype-specific case. ILI patients 
presenting in weeks of onset after two or more consecutive weeks of 
no cases and influenza A cases that were not further subtyped were 
also excluded from the analysis.
For each study site, we computed the odds ratio (OR) of being 
vaccinated in cases vs controls. We conducted a complete analysis 
excluding patients with missing values for any of the variables in the 
model measuring adjusted VE. Using Cochran’s Q- test and the I2 index, 
we tested the heterogeneity between study sites.8 We estimated the 
pooled type/subtype influenza VE as (1 minus the OR)*100 using a 
one- stage model with study site as a fixed effect.
Using a logistic regression model, we calculated VE including po-
tential confounding factors: date of symptom onset (modelled as a 
restricted cubic spline with 4 knots where sample size allowed), age 
(modelled as a restricted cubic spline with 4 knots or age groups de-
pending on the analysis), sex and presence of at least one chronic 
medical condition (including pregnancy and obesity where available). 
We used the one in ten rule of predictor degrees of freedom to events 
to determine the maximum number of covariates to include in analy-
ses with low sample sizes in order to avoid overfitting the model.9,10
To study the effect of prior (2014/15) vaccination on the 2015/16 
VE, we conducted an indicator analysis using four categories: individ-
uals unvaccinated in both seasons (reference category), vaccinated in 
2014/15 only, vaccinated in 2015/16 only and vaccinated in both sea-
sons. We did not measure effect of prior (2014/15) vaccination among 
children aged <9 years as their vaccination definition is based on pre-
vious vaccination history (children older than 6 months and less than 
9 years old who have not been vaccinated in the previous influenza 
season should receive two doses of the seasonal influenza vaccine). 
We also conducted a stratified analysis, measuring VE of the 2015/16 
vaccine among those vaccinated in 2014/15 and separately among 
those not vaccinated in 2014/15.
We measured VE by age group (0- 14, 15- 64 and 65 years and 
older), by type of vaccine (inactivated subunit and inactivated split vi-
rion) and in the target group for vaccination. We tested for interaction 
between vaccination and age group, chronic medical condition, onset 
month and sex, using the likelihood ratio test to compare the additive 
model with the interaction.
To study the effects of waning on the vaccine effect within a sea-
son, we further estimated VE by time since vaccination, modelling days 
between vaccination and symptom onset dates as a restricted cubic 
spline with 4 knots.11 In this analysis, we additionally included patients 
vaccinated 14 days or less before symptom onset (excluded from the 
main analysis).
Nine study sites participated in a laboratory pilot project (DE, FR, 
HU, IE, PT, RO, SE, ES and NL) for sequencing at least the haemagglu-
tinin gene segment for each influenza type/subtype. In this labora-
tory pilot project, either all specimens were selected for sequencing 
or a proportion of specimens were randomly selected for sequencing 
to ensure representativity. The proportion of specimens randomly 
selected for sequencing could vary over time (eg, higher early in the 
season and lower during the peak) and a sampling fraction was cal-
culated for each study site and time unit. The specimens were sent 
to the corresponding National Influenza Centre, where influenza di-
agnosis was confirmed, and viruses were characterised by sequenc-
ing the HA1 coding portion of the haemagglutinin gene. Analysis of 
the nucleotide and amino acid sequences of the HA1 coding portion 
of the haemagglutinin gene was performed in MEGA6 to determine 
clade distribution.
We weighted the genetic group- specific VE analysis using the re-
ciprocal of the sequencing sampling fraction for each time period and 
study site and used robust standard errors.
Data management and statistical analyses were carried out using 
Stata 14 (StataCorp. 2015. College Station, TX, USA).
3  | RESULTS
The 2015/16 influenza season in Europe was characterised by the 
cocirculation of influenza A(H1N1)pdm09 and influenza B viruses 
(Figure 1). Influenza A(H3N2) viruses circulated at very low levels. The 
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study period ranged from week 44/2015 to week 18/2016 for influ-
enza A(H1N1)pdm09 with cases peaking in week 4/2016 and from 
week 45/2015 to week 19/2016 for influenza B, with cases peaking 
in week 9/2016.
Of the 14 294 ILI patients recruited, 11 430 met the eligibility cri-
teria (5410 cases and 6020 controls). In the influenza type/subtype- 
specific analysis, 2272 cases of influenza A(H1N1)pdm09 and 2901 
cases of influenza B were included (Figure 2). We did not include the 
172 patients testing positive for influenza A(H3N2) in the analysis due 
to small sample size.
The proportion vaccinated with the 2015/16 influenza vaccine 
was 9.7% among controls, 6.7% among influenza A(H1N1)pdm09 
cases and 6.3% among influenza B cases (Table 1).
The median age of influenza A(H1N1)pdm09 cases was 35 years, 
of controls 29 years and of influenza B cases 12 years (Table 2). 
Compared to influenza A(H1N1)pdm09, a higher proportion of influ-
enza B cases were less than 15 years (55.3% vs 30.3%) and a lower 
proportion were 15- 64 years old (40.8% vs 63.5%). The proportion of 
patients aged 65 and older varied between controls, influenza A(H1N1)
pdm09 and influenza B cases with 9.5%, 6.2% and 3.9%, respectively.
The proportion of patients with at least one chronic condition was 
similar between controls and influenza A(H1N1)pdm09 cases (20.2% 
and 17.6%, respectively), but lower among influenza B cases (11.9%).
Among controls, 81.7% were swabbed within 3 days of symptom 
onset compared to 84.9% and 85.2% of influenza A(H1N1)pdm09 and 
influenza B cases, respectively. Among controls, 6.5% were swabbed 
on the day of symptom onset, compared to 4.2% and 4.3% of influenza 
A(H1N1)pdm09 and influenza B cases, respectively.
In total, 10.6% of controls had received both the 2014/15 and the 
2015/16 vaccines compared to 7.3% and 6.2% of influenza A(H1N1)
pdm09 and B cases, respectively. The proportion of unvaccinated in 
the current and previous season was 89.2% for influenza A(H1N1)
pdm09 cases, 90.1% for influenza B cases and 83.6% for controls.
Information on vaccine type received was available for 470 (83.3%) 
of vaccinated controls, 130 (86.7%) vaccinated influenza A(H1N1)
pdm09 and 149 (82.2%) vaccinated influenza B cases. Trivalent inacti-
vated subunit and trivalent inactivated split virion vaccines were used 
among 43.4% and 43.0% of vaccinated controls, 43.8% and 49.2% of 
vaccinated influenza A(H1N1)pdm09 cases and 45.9% and 48.0% of 
vaccinated influenza B cases, respectively.
From the 11 430 patients meeting the eligibility criteria, we fur-
ther excluded patients with missing information on 2015/16 seasonal 
vaccination status or date, onset/swab date, age, sex or presence of 
chronic condition. We included 7358 patients for the complete case 
analysis of VE against influenza A(H1N1)pdm09 and 7400 patients for 
the analysis against influenza B among all ages (Figure 2). For the com-
plete case analysis restricted to the target group for vaccination, we 
included 1953 patients (520 influenza A(H1N1)pdm09 cases) in the 
analysis of VE against A(H1N1)pdm09 and 1578 patients (409 influ-
enza B cases) in the analysis of VE against influenza B.
3.1 | Influenza A(H1N1)pdm09
Statistical heterogeneity between VE estimates against influenza 
A(H1N1)pdm09 by study site was low overall (among all ages) and 
among those aged 15- 64 years (I2 index 0% and 10%, respectively). 
Due to small sample sizes, it was not possible to estimate heterogene-
ity among other age groups.
The adjusted VE in the total population (all ages) against influenza 
A(H1N1)pdm09 was 32.9% (95% CI: 15.5- 46.7) (Table 2). The ad-
justed VE against influenza A(H1N1)pdm09 was 31.9% (95% CI: −32.3 
to 65.0) among the 0- to 14- year- olds and 41.4% (95% CI: 20.5- 56.7) 
among the 15- to 64- year- olds. Among the target group for vaccina-
tion, VE (all ages) was 33.0% (95% CI: 10.8- 49.7). It was 55.5% (95% 
CI: −35.1 to 85.3) and 42.9% (95% CI: 14.5- 61.9) among those aged 
0- 14 and 15- 64 years, respectively. Among those aged 65 years and 
older, VE adjusted for age and study site was 13.2% (95% CI: −38.0 
to 45.3).
The adjusted VE for trivalent inactivated subunit vaccine against 
influenza A(H1N1)pdm09 (all ages) was 33.9% (95% CI: 6.7- 53.1) and 
for trivalent inactivated split virion vaccine 36.9% (95% CI: 10.8- 54.5) 
(Table 2).
Information on prior vaccination status was missing among 6.7% 
of ILI patients (restricting to those 9 years and older). When using the 
indicator analysis, with the reference of those not vaccinated in the 
current or previous season, the VE among those aged 9 years and 
F IGURE  1 Number of influenza- like 
illness (ILI) reports by case status, week of 
symptom onset and influenza virus type/
subtype, total population, I- MOVE/I- 
MOVE+ multicentre case- control study, 
influenza season 2015/16, weeks 
35/2015- week 20/2016 (study period with 
influenza- positive cases: week 41/2015- 
week 19/2016)
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older against influenza A(H1N1)pdm09 was 54.7% for those who re-
ceived 2015/16 seasonal influenza vaccine only (95% CI: 19.6- 74.5), 
8.0 (95% CI: −39.3 to 39.2) for those who received prior (2014/15) 
vaccine only and 28.4% (95% CI: 6.2- 45.4) for those who received 
both 2015/16 and 2014/15 season vaccine (Table 2).
In the stratified analysis, the VE of current influenza vaccination 
against A(H1N1)pdm09 among those aged 9 years and older was 
56.2% (full model adjusted, 95% CI: 22.2- 75.3) among those not vac-
cinated in 2014/15 and 6.9% (adjusted by age and study size, 95% CI: 
−51.5 to 42.8) among those vaccinated in 2014/15.
When modelling VE by time since vaccination, VE against influ-
enza A(H1N1)pdm09 among all ages increased to 49.8% at 45 days 
since vaccination and declined to 9.3% at 218 days since vaccination 
(Figure 3).
During the study period where specimens were sequenced, the 
nine sites participating in the laboratory pilot season genetically char-
acterised 723 of 2087 (34.6%) influenza A(H1N1)pdm09 specimens 
among all ages. Of these, 15 (2.1%) belonged to the genetic group 
represented by A/England/377/2015 (genetic group 6B.2), 56 (7.7%) 
to the genetic group represented by A/SouthAfrica/3626/2013 
F IGURE  2 Flow chart of data exclusion 
for pooled analysis. I- MOVE/I- MOVE+ 
multicentre case- control study, influenza 
season 2015/16 (week 41/2015- week 
19/2016)
Number of records received for pooled analysis:
14 294
Excluding records:
• Persons with contraindicaons against vaccinaon (N = 0)
• Persons administered anvirals prior to swabbing (N = 15)
• Persons with missing laboratory results  (N = 17)
• Persons with missing onset date (N = 295)
• With date of onset <15 days aer begin of vaccinaon campaign (N = 261)
• Not meeng the EU ILI case definion (N = 1461)or EU ILI status unknown (N = 106)
• With interval between onset of symptoms and swabbing >7 days (N = 449)
• With controls prior to onset week of first influenza case (260)
Dropping records with missing data for complete case analysis:
Influenza B analysis
Influenza A(H1N1) pdm09
analysis
• Dropping influenza posive records of different type/subtype and excluding paents presenng before ISO
week of first type/subtype-specific influenza case and aer ISO week of last type/subtype-specific influenza
case aer which there are two consecuve weeks of no cases (weeks of symptom onset, by country)
a Includes 19 influenza B+A(H1N1)pdm09 coinfecons
b Includes 1 influenza B+A(H3N2) coinfecon
c Includes 18 influenza B+A(H1N1)pdm09 coinfecons
d Include 4 B+A(H1N1)pdm009 coinfecons
Influenza B analysis
(N = 204)
(N = 150)
Influenza A(H1N1) pdm09
analysis
(N = 245)
(N = 150)
• Persons with missing informaon on age, sex or chronic disease
• Persons with missing 2015/16 influenza vaccinaon status or date
7753
Cases: 2272a
Controls: 5481
7754
Cases: 2901 a,b
Controls: 4853
7358
Cases: 2176c
Controls: 5182
7400
Cases: 2787c
Controls: 4613
11 430
Cases: 5410
Controls: 6020
Target group for vaccinaon (complete case analysis):
1953
Cases: 520d
Controls: 1433
1578
Cases: 409d
Controls: 1169
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TABLE  1 Details for influenza A(H1N1)pdm09 (n = 2272) and influenza B cases (n = 2901) and controls (n = 1650) included in the 2015/16 
season influenza vaccine effectiveness analysis (week 41/2015- week 19/2016), I- MOVE/I- MOVE+ multicentre case- control study
Variables
Number of test- negative  
controls a/total n (%)
Number of influenza A(H1N1) 
pdm09/total n (%)
Number of influenza 
B cases/total n (%)
Median age (years) 29.0 35.0 12.0
Age groups
0- 4 1437/6004 (23.9) 365/2268 (16.1) 536/2894 (18.5)
5- 14 739/6004 (12.3) 321/2268 (14.2) 1064/2894 (36.8)
15- 64 3255/6004 (54.2) 1441/2268 (63.5) 1182/2894 (40.8)
≥65 573/6004 (9.5) 141/2268 (6.2) 112/2894 (3.9)
Missing 16 4 7
Sex
Female 3159/5975 (52.9) 1137/2259 (50.3) 1456/2871 (50.7)
Missing 45 13 30
Days between onset of symptoms and swabbing
0 389/6020 (6.5) 95/2272 (4.2) 126/2901 (4.3)
1 2008/6020 (33.4) 824/2272 (36.3) 907/2901 (31.3)
2 1589/6020 (26.4) 663/2272 (29.2) 899/2901 (31.0)
3 934/6020 (15.5) 348/2272 (15.3) 539/2901 (18.6)
4- 7 1100/6020 (18.3) 342/2272 (15.1) 430/2901 (14.8)
Seasonal vaccination, 2015/16 564/5802 (9.7) 150/2223 (6.7) 180/2841 (6.3)
Vaccinated <15 d before onset of symptoms 17 0 0
Missing 201 49 60
Prior season influenza vaccinationb
Not vaccinated in any season 3259/3896 (83.6) 1421/1593 (89.2) 1481/1635 (90.1)
Current season (2015/16) vaccination only 87/3896 (2.2) 17/1593 (1.1) 19/1635 (1.2)
Prior (2014/15) season vaccination only 138/3896 (3.5) 39/1593 (2.4) 33/1635 (2.0)
Current and prior season vaccination 412/3896 (10.6) 116/1593 (7.3) 102/1635 (6.2)
Missing or vaccinated <15 d before onset 279 109 69
Seasonal vaccination type
Not vaccinated 5255/5819 (90.3) 2073/2203 (93.3) 2661/2809 (93.7)
Inactivated subunit 204/5819 (3.5) 57/2203 (2.6) 68/2809 (2.4)
Inactivated split virion trivalent 202/5819 (3.5) 64/2203 (2.9) 71/2809 (2.5)
Adjuvantedc 60/5819 (1.0) 6/2203 (0.3) 6/2809 (0.2)
Inactivated cell- derived subunit 1/5819 (0.0) 0/2203 (0.0) 0/2809 (0)
Quadrivalent vaccined 3/5819 (0.1) 3/2203 (0.1) 3/2809 (0.1)
Unknown vaccine type 94/5819 (1.6) 20/2203 (0.9) 32/2809 (1.1)
Missing vaccination status or date or 
vaccinated <15 d before onset
81 49 60
At least one chronic condition 1194/5900 (20.2) 391/2227 (17.6) 341/2870 (11.9)
Missing 120 45 31
At least one hospitalisation in the previous 
12mo for chronic conditions
110/5857 (1.9) 26/2214 (1.2) 21/2854 (0.7)
Missing 163 58 47
Belongs to the target group for vaccination 1648/5931 (27.8) 544/2236 (24.3) 434/2873 (15.1)
Missing 89 36 28
Study sites
Croatia 39/6020 (0.6) 15/2272 (0.7) 19/2901 (0.7)
(Continues)
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(genetic group 6B) and 652 (90.2%) to the genetic group represented 
by A/Slovenia/2903/2015 (genetic group 6B.1)(Table 3). The adjusted 
VE against 6B.1 was 32.8% (95% CI: −4.1 to 56.7) overall for all age 
groups, 51.3% (95% CI: −33.5 to 82.3) among the 0- to 14- year- old 
and 40.1% (95% CI: −12.9 to 68.3) among 15- to 64- year- old age 
groups (Table 2). The sample size was too small to calculate VE for 
those aged 65 years and older.
3.2 | Influenza B
The I2 index for heterogeneity between VE estimates against influ-
enza B by study site was 56% among all ages and 0% among those 
aged 15- 64 years. Due to small sample size, it was not possible to es-
timate heterogeneity among those aged 65 years and older. Among 
children, we could measure the I2 between three countries (DE, FR 
and IT; in all other countries, less than 5 children were vaccinated), 
which was 0%.
The adjusted VE against influenza B was −47.6% (95% CI: −124.9 
to 3.1) among the 0- to 14- year- olds and 27.3% (95% CI: −4.6 to 49.4) 
among the 15- to 64- year- olds (Table 2). Crude VE was 9.3% (95% 
CI: −44.1 to 42.9) among those aged 65 years and older (all belong 
to the target group for vaccination only), and the small sample size 
did not allow for adjusted VE estimates. The chi- square of the like-
lihood ratio test for interaction between vaccine and age group was 
24.0 (P < .001). Due to this strong interaction between age group and 
vaccine, we did not attempt to calculate an overall (all ages) VE. The 
adjusted VE among the target group for vaccination was 1.7% (95% 
CI: −94.5 to 50.3) and 38.4% (95% CI: −6.6 to 64.4) among those aged 
0- 14 and 15- 64 years, respectively.
The adjusted VE for trivalent inactivated subunit vaccine against 
influenza B among those aged 0- 14 years was −56.4% (95% CI: 
−202.1 to 19.0) and for split virion vaccine −83.5% (95% CI: −232.9 
to 1.1) (Table 3). For those aged 15- 64 years, it was 17.7% (95% CI: 
−48.0 to 54.3) for subunit vaccine and 44.4% (95% CI: −2.8 to 70.0) 
for split virion vaccine.
Information on prior vaccination status was missing in 5.1% of ILI 
patients (restricting to those 9 years and older). When using the indi-
cator analysis, with the reference of those not vaccinated in the cur-
rent or previous season, the VE among 15- to 64- year- olds receiving 
the current 2015/16 seasonal influenza vaccine only was 28.3% (95% 
CI: −40.2 to 63.3), 41.3 (95% CI: −8.7 to 68.3) among those receiv-
ing prior season (2014/15) vaccine only and 23.7% (95% CI: −16.8 
to 50.2) among those who received both 2015/16 and prior season 
(2014/15) vaccine (Table 2).
In the stratified analysis, the VE of current influenza vaccina-
tion against influenza B among 15- to 64- year- olds was 28.7% (95% 
CI: −39.6 to 63.5) among those who did not receive prior season 
(2014/15) vaccine. We could not compute VE of current influenza 
vaccination among those who received prior season (2014/15) due to 
small sample size.
When modelling VE by time since vaccination among those aged 
15 years and older, VE against influenza B ranged from 2.3% at 
218 days to 36.6% at 60 days (Figure 3).
Of the 2901 influenza B cases (all ages), 2132 (73.5%) had 
known B/lineage. Among these, 2.7% were B/Yamagata lineage (57) 
and 97.3% were B/Victoria lineage (2075). Among the 8 of 9 pilot 
laboratory study sites that sequenced B- positive specimens, 321 of 
2416 were sequenced (13.3%) (Table 3). Twelve (3.7%) belonged to 
the genetic group represented by B/Phuket/3073/2013 (Yamagata 
lineage) group 3. Among the 309 (96.3%) that belonged to the ge-
netic group represented by B/Brisbane/60/2008 (Victoria lineage), 
all belonged to genetic group 1A, and 308 of them had N129D 
amino acid substitutions, and one had K56N and V124A amino acid 
substitutions.
Variables
Number of test- negative  
controls a/total n (%)
Number of influenza A(H1N1) 
pdm09/total n (%)
Number of influenza 
B cases/total n (%)
France 1471/6020 (24.4) 508/2272 (22.4) 1294/2901 (44.6)
Germany 1726/6020 (28.7) 436/2272 (19.2) 571/2901 (19.7)
Hungary 593/6020 (9.9) 54/2272 (2.4) 112/2901 (3.9)
Ireland 241/6020 (4.0) 181/2272 (8) 130/2901 (4.5)
Italy 498/6020 (8.3) 34/2272 (1.5) 390/2901 (13.4)
Poland 312/6020 (5.2) 136/2272 (6.0) 65/2901 (2.2)
Portugal 186/6020 (3.1) 111/2272 (4.9) 11/2901 (0.4)
Romania 80/6020 (1.3) 61/2272 (2.7) 0/2901 (0.0)
Spain 286/6020 (4.8) 447/2272 (19.7) 165/2901 (5.7)
Sweden 376/6020 (6.2) 175/2272 (7.7) 65/2901 (2.2)
The Netherlands 212/6020 (3.5) 114/2272 (5.0) 79/2901 (2.7)
aControls for “any influenza” used here (number of controls differs slightly for influenza A(H1N1)pdm09 and B analyses, due to the inclusion criteria).
bAmong patients aged 9 y and over.
cIncludes squalene (MF59), virosome and aluminium phosphate gel adjuvants.
dIncludes Fluenz Tetra (nasal spray) as well as Fluarix Tetra (injectable).
TABLE  1  (Continued)
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4  | DISCUSSION
The 2015/16 influenza VE against medically attended ILI due to in-
fluenza A(H1N1)pmd09 in the I- MOVE/I- MOVE+ multicentre case- 
control study in Europe ranged from 13.2% to 55.5% in the total 
and target population, depending on age group. There was a very 
low VE or no protective effect against influenza B among the 0- to 
14- year- olds and VE among the 15- to 64- year- olds among the total 
and target population ranged from 27.3% to 38.4%.
In the 2015/16 season, twelve study sites contributed to the I- 
MOVE multicentre case- control study and 11 430 individuals were 
included. This is the largest sample size since the network began in 
2008/09. The number of vaccinated patients remains low, even among 
the target group for vaccination, with 29%- 30% of controls vaccinated. 
Despite the large sample size, this results in a reduced precision, which 
is one of the limitations of the study.
Vaccine effectiveness (VE) point estimates against influenza 
A(H1N1)pdm09 were lower in 2015/16 than in 2014/15, overall 
and by each age group (54.2, 73.1, 59.7 and 22.4 for all ages, 0- to 
14- year- olds, 15- to 59- year- olds and those aged 60 and older, re-
spectively). Vaccine effectiveness (VE) point estimates against 
A(H1N1)pdm09 were also lower in Canada and in the USA, compared 
to 2013/14, the last year where influenza A(H1N1)pdm09 was a 
dominant or codominant circulating strain in these countries.12-15 We 
observed a low influenza A(H1N1)pdm09 VE point estimate among 
those aged 65 years and older that was not seen in other studies in 
F IGURE  3 Adjusted vaccine 
effectiveness (VE) and 95% CI against 
influenza A(H1N1)pdm09 (all ages) and 
influenza B (15 y and older) by time since 
vaccination, total population, I- MOVE/I- 
MOVE+ multicentre case- control study, 
influenza season 2015/16 (week 41/2015- 
week 19/2016)
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2015/16.14,16,17 However, in our study, the number of individuals in 
this age group was low and VE was only adjusted by age and study site.
The results suggest a decrease in VE with time since vaccination 
against influenza A(H1N1)pdm09 across this long and late season. 
While the decrease is mild and precision around the estimate is low, 
this is the first season where we observed this decrease in influenza 
A(H1N1)pdm09 VE.11 A decline in VE against influenza A(H1N1)
pdm09 with time across the season was also suggested in the 2015/16 
season in Canada.12 However, more research on the effects of immu-
nity along the season and the in- season decline in VE would be useful 
to validate the results.
In the 2014/15 season, the influenza A(H1N1)pdm09 genetic 
group 6B dominated, and in 2015/16, a major genetic variant, 6B.1, 
defined by the HA1 amino acid substitutions S84N, S162N and 
I216T emerged. For the sites participating in the pilot laboratory 
project, 90.2% of all sequenced influenza A(H1N1)pdm09 specimens 
belonged to the 6B.1 genetic group. Antigenic characterisation by 
haemagglutinin inhibition (HI) assay of circulating influenza A(H1N1)
pdm09 viruses from EU/EEA countries using ferret sera indicated that 
they were antigenically similar to the vaccine virus.18 However, 6B.1 
viruses were poorly inhibited by some post- vaccination human serum 
pools and WHO recommends an influenza A/Michigan/45/2015 
(H1N1)pdm09- like virus (6B.1 genetic group) for the 2017 Southern 
Hemisphere influenza vaccine.19 It is possible that the lower VE point 
estimate against influenza A(H1N1)pdm09 in the I- MOVE/I- MOVE+ 
study in 2015- 16 may be linked to the changes in the circulating strain 
compared to the vaccine strain.
The VE point estimate against influenza A(H1N1)pdm09 for those 
receiving 2015/16 season vaccine only was higher than that among 
those receiving both 2014/15 and 2015/16 vaccines. While the two 
estimates are never statistically different from each other, the pattern 
looks like those from the negative interference hypothesis: that in-
terference from previous season vaccine may be present when con-
secutive season vaccine components are similar and there is a large 
antigenic distance between the circulating and vaccine strain.20 The 
2015/16 and 2014/15 influenza A(H1N1)pdm09 vaccine strains 
were identical; however, more evidence is needed to determine the 
antigenic distance between the vaccine strain (A/California/7/2009 
(H1N1)pdm09- like virus) and the 6B.1 circulating genetic group. This 
pattern was not seen in the 2014/15 season, where vaccine strains 
were identical and the circulating strain was the 6B genetic group 
(current and prior season VE point estimates: 47.2% and 52.7%, re-
spectively).21 Alternative and also likely explanations for the 2015/16 
results may be random variation due to a low vaccination coverage 
and confounding due to different participant profiles of repeat and 
single- season vaccinees.
The VE point estimate of subunit vaccine against influenza A(H1N1)
pdm09 was higher than that of split virion among 0- to 14- year- olds, 
but the same among 15- to 59- year- olds. However, precision is low 
due to small numbers of vaccinated. Age- specific VE estimates for vac-
cine groups are not available in previous I- MOVE study publications 
and would be useful going forward, numbers of vaccinated allowing.
This is the first season in which the I- MOVE study could provide 
representative VE estimates against an influenza genetic group. This 
represents great progress, although precision around the age- stratified 
estimates is low. In the 2015/16 season, there was only one major ge-
netic group circulating. In seasons where two or more genetic clades 
are cocirculating, more sequencing is needed to obtain a reasonable 
precision. Precise genetic group- specific estimates provide important 
information for interpreting overall VE results and VE results by time 
since vaccination.
The VE against influenza B was very low or may have conferred 
no protection among children and was low to moderate among 15- to 
64- year- olds. The differences in VE between age groups were large 
(P < .001). In the context of this effect modification and differential 
age distributions between studies, due to different healthcare- seeking 
behaviours and practitioners included in the study (France, Italy, 
Germany and Spain include paediatricians in the study), providing a 
VE among all ages was not appropriate. The age- specific effect mod-
ification and differential age distribution may explain in part why the 
heterogeneity of study site- specific estimates among all ages was 
moderate to high (I2 = 55.9%).
In the UK and the USA, the 2015/16 VE against influenza B 
among children was higher than in the I- MOVE/I- MOVE+ multicentre 
TABLE  3  Influenza A(H1N1)pdm09, influenza B/Yamagata and influenza B/Victoria viruses characterised by clade and study site, study sites 
participating in the laboratory pilot study, I- MOVE multicentre case- control study, Europe, influenza season 2015/6 (week 41/2015- week 
16/2016)
Characterised viruses Genetic group DE FR HU IE PT RO ES SE NL Total (%)
Influenza A(H1N1)pdm09
A/England/377/2015 6B.2 3 8 0 0 0 2 1 1 0 15 (2.1)
A/SouthAfrica/3626/2013 6B 4 1 1 1 12 2 30 0 5 56 (7.7)
A/Slovenia/2903/2015 6B.1 143 83 19 15 76 27 245 20 24 652 (90.2)
Total 150 92 20 16 88 31 276 21 29 723
Influenza B
B/Phuket/3073/2013 3 11 0 0 0 - - 0 1 0 12 (3.7)
B/Brisbane/60/2008 1A 135 85 32 5 - - 9 15 28 309 (96.3)
Total 146 85 32 5 - - 9 16 28 321
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case- control study. The VE was 56.3% in the UK among those children 
receiving the (predominantly trivalent) inactivated injectable vaccine, 
and in the USA, the VE was 64% against B/Yamagata and 56% against 
B/Victoria among those children receiving the (predominantly quad-
rivalent) inactivated injectable vaccine.14,17 A low VE among children 
was seen in Finland receiving the (predominantly trivalent) inactivated 
injectable vaccine (−1%).22 In the USA, there is a universal vaccination 
recommendation, and in the UK and Finland, vaccine is recommended 
in certain age groups in children. However, in the countries participat-
ing in the I- MOVE/I- MOVE+ multicentre case- control study, vaccine 
is recommended only to children with chronic conditions, with the ex-
ception of Poland where vaccination is recommended among those 
aged 6 months to 18 years.23-25
The low VE against influenza B in children in the I- MOVE/I- 
MOVE+ multicentre case- control study in the 2015/16 season is in 
contrast to 2014/15 where VE against influenza B was 62.1% (95% CI: 
14.9- 83.1).21 While a selection bias among children could explain the 
low VE against influenza B, the higher VE against influenza A(H1N1)
pdm09 among children (31.9%) and the high VE in the 2014/15 sea-
son suggest otherwise. Few children in the 2015/16 study were vac-
cinated with the quadrivalent vaccine (4.4% among those vaccinated 
children with known vaccine product).
The crude VE against influenza B in those aged 65 years and 
older was low as observed in the UK (−20.2%), in Danish interim 
estimates (4.1%; hospital- based patients included) and in the USA 
(−34%; B Flannery, personal communication, 8 March 2017) 2015- 16 
season.16,17
In the 2015/16 season, the circulating strains were antigenically 
distinct from the strain selected for the influenza B component in 
the trivalent influenza vaccine. Nevertheless, there was VE of 27.3% 
among the 15- to 64- year- olds. Varying levels of cross- protection have 
been reported previously.26-28 In the 2015/16 season, our VE point 
estimates are less than 10% among those aged 0- 14 years and those 
aged 65 years and above. Among older adults and children, the differ-
ences observed in VE in a season of mismatch between the vaccine 
and circulating strains may be explained by a combination of immune 
system properties specific to children and the elderly, as well as by the 
role of previous vaccinations and previous infections.
The VE point estimate was higher for subunit vaccine than for split 
virion vaccine among children, but precision was low. Both estimates 
were low, indicating that the low VE was not due to a vaccine type- 
specific issue. Among 15- to 64- year- olds, split virion VE point esti-
mate was higher than subunit vaccine, but again precision was low.
In our study, there is residual protection of the prior (2014/15) sea-
son vaccine against influenza B among the 15- to 64- year- olds. The 
2014/15 trivalent vaccine also contained a B/Yamagata virus, mis-
matched with regard to the lineage circulating in 2015/16. Vaccination 
in current and previous season resulted in a similar VE against influenza 
B among 15- to 59- year- olds as vaccination with current vaccine only.
In the 2015/16 influenza season, the results of I- MOVE/I- MOVE+ 
study suggest a lower VE against influenza A(H1N1)pdm09 and influ-
enza B than in previous seasons. Both the low VE against influenza 
B in children and older adults and the low to moderate VE against 
influenza B among younger adults may be important in the context of 
cost- effectiveness studies looking into recommendations for quadri-
valent vaccines and for more precise data need to be collected. Lower 
VE against influenza A(H1N1)pdm09 in the 2015/16 season, as well 
as the indications of the effects of previous vaccination seen here and 
elsewhere need to be evaluated in subsequent seasons together with 
virological and immunological results.
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